Recommendation of the President – Uplizna (inebilizumab)

On 13 May 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 58/2025 on the appraisal of drug Uplizna (inebilizumab) under the drug program B.138.FM “Treatment of patients with neuromyelitis optica spectrum disorder (NMOSD) (ICD-10: G36.0)”

Publication in Public Information Bulletin (BIP) >>